New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:20 EDTUTHR, MDVN, CBST, ALKS, SLXP, JAZZ, AUXL, NPSP, HSP, AKRXLeerink names top 10 acquisition candidates in biopharma
Leerink believes partnership and acquisition activity will remain a key feature of news flow and excess returns for investors in the biopharma industry during 2014 and into 2015. The firm's top 10 acquisition candidates in the space are: Alkermes (ALKS), Akorn (AKRX), Akorn (AUXL), Cubist (CBST), Hospira (HSP), Jazz Pharmaceuticals (JAZZ), Medivation (MDVN), NPS Pharmaceuticals (NPSP), Salix (SLXP) and United Therapeutics (UTHR).
News For ALKS;AKRX;AUXL;CBST;HSP;JAZZ;MDVN;NPSP;SLXP;UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
08:12 EDTJAZZJazz Pharmaceuticals management to meet with Leerink
Subscribe for More Information
07:21 EDTJAZZUBS to hold a conference
Subscribe for More Information
May 18, 2015
12:24 EDTJAZZJazz Pharmaceuticals management to meet with Guggenheim
Subscribe for More Information
10:01 EDTUTHROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: A10 Networks (ATEN) upgraded to Overweight from Sector Weight at Pacific Crest... Cal-Maine Foods (CALM) upgraded to Overweight from Equal Weight at Stephens... ChemoCentryx (CCXI) upgraded to Overweight from Neutral at JPMorgan... Cheniere Energy Partners LP (CQP) upgraded to Buy from Neutral at Goldman... Chicago Bridge & Iron (CBI) upgraded to Neutral from Sell at Goldman... Continental Resources (CLR) upgraded to Buy from Neutral at Goldman... Ctrip.com (CTRP) upgraded to Overweight from Neutral at JPMorgan... Emerge Energy (EMES) upgraded to Buy from Neutral at Goldman... FEMSA (FMX) upgraded to Overweight from Equal Weight at Morgan Stanley... GoPro (GPRO) upgraded to Perform from Underperform at Oppenheimer... Holly Energy (HEP) upgraded to Buy from Neutral at Goldman... JP Energy (JPEP) upgraded on better visibility on volumes at RBC Capital... Laredo Petroleum (LPI) upgraded to Neutral from Sell at Goldman... Malvern Bancorp (MLVF) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Goldman... Norsk Hydro (NHYDY) upgraded to Overweight from Neutral at JPMorgan... Owens-Illinois (OI) upgraded to Neutral from Underperform at BofA/Merrill... Penn National (PENN) upgraded to Buy from Neutral at Goldman... Roche (RHHBY) upgraded to Buy from Neutral at UBS... Schnitzer Steel (SCHN) upgraded on stabilizing headwinds at KeyBanc... Seventy Seven Energy (SSE) upgraded to Buy from Hold at Jefferies... Toll Brothers (TOL) upgraded to Neutral from Underperform at Sterne Agee CRT... United Therapeutics (UTHR) upgraded to Buy from Neutral at BTIG... Volvo (VOLVY) upgraded to Neutral from Underweight at JPMorgan... Zayo Group (ZAYO) upgraded to Buy from Neutral at Goldman.
08:10 EDTUTHRUnited Therapeutics upgraded to Buy from Neutral at BTIG
Subscribe for More Information
07:21 EDTAKRXAkorn receives NASDAQ delinquency notice
Subscribe for More Information
May 17, 2015
12:53 EDTMDVNMedivation, Astellas report enzalutamide study met primary endpoint
Subscribe for More Information
May 15, 2015
10:29 EDTCBSTAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTUTHRAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
07:35 EDTMDVNMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
May 14, 2015
12:29 EDTHSPPfizer receives 'second request' from FTC regarding potential Hospira merger
Subscribe for More Information
07:07 EDTMDVNMedivation to present data in TNBC at ASCO
Medivation announced that the following abstract will be presented during an oral presentation at the 2015 American Society of Clinical Oncology, or ASCO, Annual Meeting on June 1, in Chicago: Results from a phase 2 study of enzalutamide, an androgen receptor, or AR, inhibitor, in advanced AR+ triple-negative breast cancer, or TNBC.
May 13, 2015
19:17 EDTHSPHospira and FDA detect security vulnerabilities in infusion pumps
Subscribe for More Information
13:43 EDTHSPHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.
May 12, 2015
07:52 EDTALKSLeerink to hold a tour
Subscribe for More Information
May 11, 2015
06:19 EDTALKSAlkermes management to meet with Jefferies
Meeting to be held in Baltimore on May 11 hosted by Jefferies.
May 8, 2015
16:11 EDTAKRXAkorn files to delay 10-Q
Subscribe for More Information
11:39 EDTJAZZFlamel jumps after competitors scrap narcolepsy drug development
Subscribe for More Information
07:15 EDTMDVNMedivation price target raised to $142 from $130 at UBS
Subscribe for More Information
06:59 EDTMDVNMedivation weakness a buying opportunity, says William Blair
William Blair recommends using the post-earnings weakness in shares of Medivation as a buying opportunity. The firm believes Xtandi sales growth in prostate cancer remains strong despite the Q1 miss and raised its price target for shares to $154 from $144. It keeps an Outperform rating on the name.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use